indazoles has been researched along with 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonazzi, VF; Cummings, MC; Geng, X; Ju, RJ; Mahon, CE; Packer, LM; Pollock, PM; Stephenson, SA | 1 |
| Bhutkar, A; Chen, PY; Chung, KM; Dorans, KJ; Hong, E; Jacks, T; Muzumdar, MD; Noll, EM; Sprick, MR; Trumpp, A | 1 |
| Grad, I; Han, J; Hanes, R; Karlsen, I; McCormack, E; Meza-Zepeda, LA; Munthe, E; Myklebost, O; Stratford, EW | 1 |
3 other study(ies) available for indazoles and 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
| Article | Year |
|---|---|
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Morpholines; Mutation; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Sulfonamides; Thiazoles; Xenograft Model Antitumor Assays | 2017 |
Survival of pancreatic cancer cells lacking KRAS function.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; DNA Copy Number Variations; Humans; Immunoblotting; Indazoles; Mice; Morpholines; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Purines; Pyrimidines; Pyrimidinones; Quinazolinones; Sulfonamides; Thiazoles | 2017 |
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Gene Amplification; Humans; Indazoles; Liposarcoma; MAP Kinase Signaling System; Membrane Proteins; Mice; Phenylurea Compounds; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Treatment Outcome | 2019 |